Anti-Cancer Drugs Acalabrutinib: Jiyya Ga CLL / SLL / MCL - AASraw
AASraw yana samar da NMN da NRC foda a cikin girma!

Magungunan Anti-Cancer Acalabrutinib

 

  1. Acalabrutinib Backgroud
  2. Ra'ayoyin Acalabrutinib
  3. Acalabrutinib Jiyya (An yi amfani da shi)
  4. Tsarin Acalabrutinib Na Aiki
  5. Menene sakamakon tasirin Acalabrutinib?
  6. Acalabrutinib VS Ibrutinib
  7. Bincike: Acalabrutinib akan Kula da cutar sankarar bargo ta yau da kullun (CLL)

 

Acalabrutinib Backgroud

Zuwa yau, ana amfani da acalabrutinib a gwajin da ke nazarin maganin B-All, Myelofibrosis, Ovarian Cancer, Multiple Myeloma, da Hodgkin Lymphoma, da sauransu.

Ya zuwa Oktoba 31, 2017 FDA ta amince da Astra Zeneca ta yin magana da Calquence (acalabrutinib). Wannan Bruton Tyrosine Kinase (BTK) mai hanawa ya nuna don maganin cutar sankarar bargo ta lymphocytic, ƙaramin lymphocytic lymphoma, kuma a cikin majiyyata manya da Mantle Cell Lymphoma (MCL) waɗanda tuni sun karɓi aƙalla magani guda na farko.

Har ila yau, da aka sani da ACP-196, acalabrutinib kuma ana daukar shi mai hana BTK na ƙarni na biyu saboda an ƙaddara shi da hankali don ya zama mai ƙarfi da zaɓe fiye da ibrutinib, a bisa ka'ida ana tsammanin zai nuna ƙananan sakamako masu illa saboda rage tasirin abubuwan kallo a kan abubuwan da ba na BTK ba.

Koyaya, an yarda da acalabrutinib a ƙarƙashin hanyar ingantacciyar hanyar amincewa ta FDA, wanda ya dogara da ƙimar amsawa gaba ɗaya da haɓaka fuskokin farko waɗanda suka dace da magunguna waɗanda ke kula da mawuyacin yanayi ko / kuma waɗanda ke cika buƙatun likita marasa ƙarfi bisa ga ƙarshen ƙarshen maye gurbin. Ci gaba da amincewa ga alamar acalabrutinib da aka yarda da ita a halin yanzu na iya kasancewa a kan tabbaci mai gudana da bayanin fa'idar asibiti a cikin gwajin gwaji.

Bugu da ƙari kuma, Hukumar ta FDA ta ba da wannan Binciken na Fifiko da Ingantaccen Tsarin Gyara. Hakanan ta karɓi nunin Magungunan Marayu, wanda ke ba da kwarin gwiwa don taimakawa da ƙarfafa haɓakar magunguna don cututtukan da ba safai ba. A wannan lokacin, fiye da gwaji na asibiti na 35 a cikin ƙasashe 40 tare da marasa lafiya sama da 2500 suna gudana ko an kammala su tare da gaisuwa don ƙarin bincike game da kyakkyawar fahimta da faɗaɗa amfani da magani na acalabrutinib 5.

 

Acalabrutinib reviews

Acalabrutinib (CAS:1420477-60-6), wanda aka tallatawa a ƙarƙashin sunan fata na Calquence® a Amurka da Kanada, ɗan ƙaramin ƙarfe ne mai hana ƙwayoyin cuta na Bruton's tyrosine kinase (BTK). Bayan maganganun baka, acalabrutinib yana ɗaure kuma yana iya hana aikin BTK wanda zai hana kunna B-cell da siginar sulhu na B-cell. Wannan aikin yana haifar da hana ci gaban ƙwayoyin B masu haɗari waɗanda ke nuna BTK da yawa. Ana buƙatar BTK don siginar B-cell, yana taka muhimmiyar rawa a cikin haɓakar B-cell, kuma an nuna shi da yawa a cikin mummunan cutar ta B-cell, gami da CLL / SLL. Maganar BTK a cikin ƙwayoyin tumo suna da alaƙa da ƙaruwa da rayuwa. A matsayina na mai hana BTK na ƙarni na biyu, an tsara acalabrutinib don ƙara girman sakamako akan BTK da rage ayyukan ci gaba akan TEC (Tec Protein Tyrosine Kinase), EGFR (mai karɓar haɓakar haɓakar epidermal), da ITK (interleukin-2-inducible T- cell kinase). Generationarnin farko na BTK mai hanawa, ibrutinib (Imbruvica), ba shi da wannan takamaiman abin da ke haifar da mafi girman tasirin mummunan sakamako. Baya ga CLL / SLL, acalabrutinib an yarda da Mantle Cell Lymphoma (MCL). Cibiyar Kula da Ciwon Cutar Cancer ta Kasa (NCCN) ta tsara jerin acalabrutinib tare da ko ba tare da obinituzumab a matsayin maganin layi na farko don CLL / SLL da kuma dacewa da amfani a sake dawowa ko ƙin yarda (R / R) CLL.

 

Acalabrutinib Jiyya (An yi amfani dashi)

Ana amfani da Acalabrutinib don magance mutane tare da kwayar cutar kwayar halitta ta jiki (MCL; ciwon daji mai saurin girma wanda ke farawa a cikin ƙwayoyin garkuwar jiki) waɗanda tuni aka ba su magani tare da aƙalla ɗayan sauran magunguna na chemotherapy.

Ana amfani da Acalabrutinib shi kaɗai ko tare da obinutuzumab (Gazyva) don magancewa na kullum lymphocytic cutar sankarar bargo (CLL; wani nau'in cutar kansa wanda ke farawa a cikin ƙwayoyin farin jini) da ƙananan ƙwayoyin lymphocytic lymphoma (SLL: wani nau'in ciwon daji hakan yana farawa a cikin fararen ƙwayoyin jini).

Acalabrutinib yana cikin aji na magungunan da ake kira kinase inhibitors. Yana aiki ta hanyar toshe aikin sunadarin da ba shi da kyau wanda ke nuna ƙwayoyin kansar su ninka. Wannan yana taimakawa dakatar da yaduwar kwayoyin cutar kansa.

 

Acalabrutinib inji Of Action

Mantle Cell Lymphoma (MCL) nau'ikan nau'ikan ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta ta jiki (NHL) tare da mummunan hangen nesa. Bayan haka, sake dawowa ya zama gama gari ga marasa lafiyar MCL kuma a ƙarshe yana wakiltar ci gaban cutar.

Lymphoma yana faruwa ne lokacin da ƙwayoyin cuta na kwayar cuta ke girma kuma su ninka yadda ya kamata. Irin waɗannan ƙwayoyin cuta masu kamuwa da cutar kansa na iya tafiya zuwa ɓangarorin jiki da yawa, gami da ƙwayoyin lymph, da baƙin ciki, da kashin ƙashi, da jini, da sauran gabobin inda za su iya ninka kuma su samar da wani abu wanda ake kira ƙari. Daya daga cikin manyan nau'in kwayar cutar lymphocytes wanda zai iya bunkasa zuwa cutar sankara shine cututtukan B-lymphocytes (B-cells) na jiki.

Bruton Tyrosine Kinase (BTK) sigar sigina ce ta kwayar B-cell antigen receptor da kuma hanyoyin karɓar cytokine. Irin wannan siginar BTK yana haifar da kunna hanyoyin da suka dace don yaduwar kwayar B, fataucin mutane, chemotaxis, da mannewa.

Acalabrutinib wani karamin mai hana kwayar cutar BTK ne. Dukansu acalabrutinib da kuma wanda yake amfani dashi, ACP-5862, suna aiki don samar da haɗin kai tare da ragowar cysteine ​​(Cys481) a cikin shafin BTK mai aiki, wanda ke haifar da hana BTK enzymatic aiki. siginar siginar siginar CD86 da CD69, wanda a ƙarshe ya hana mummunan ƙwayar cuta da kuma rayuwa.

Ganin cewa ibrutinib galibi ana gane shi a matsayin mai hana shiga BTK na farko, acalabrutinib ana ɗaukarsa a matsayin mai hana BTK ƙarni na biyu da farko saboda yana nuna babban zaɓi da hana ayyukan BTK da aka ƙaddamar yayin da yake da mafi girma IC50 ko kuma in ba haka ba kusan babu hanawa akan ayyukan kinase na ITK, EGFR, ERBB2, ERBB4, JAK3, BLK, FGR, FYN, HCK, LCK, LYN, SRC, da YES1.

A sakamakon haka, acalabrutinib an tsara shi da hankali don ya zama mai karfi da zabi fiye da ibrutinib, duk yayin da yake nuna karancin illoli - a ka'idar - saboda rage tasirin magungunan.

AASraw ƙwararren masani ne na Acalabrutinib.

Da fatan za a danna nan don bayanin zance: Saduwa da mu

 

Menene sakamakon tasirin Acalabrutinib?

Acalabrutinib na iya haifar da mummunar illa, gami da:

Cututtuka masu tsanani na iya faruwa yayin jiyya tare da Acalabrutinib kuma na iya haifar da mutuwa. Mai yiwuwa likitocin kula da lafiyar ka su rubuta wasu magunguna idan kana da kasadar kamuwa da cututtuka. Faɗa wa likitanka nan da nan idan kana da wasu alamu ko alamomin kamuwa da cuta, gami da zazzaɓi, sanyi, ko alamomin mura.

Matsalar zubar jini (zubar jini) na iya faruwa yayin jiyya tare da Acalabrutinib kuma yana iya zama mai tsanani kuma yana iya haifar da mutuwa. Hadarin zubar jini na iya karuwa idan kai ma kana shan magani mai rage jini. Faɗa wa likitanka idan kana da wasu alamu ko alamomi na zubar jini, gami da jini a cikin kujerun ka ko kuma baƙar baƙar fata (kama da kwalta), fitsari mai ruwan hoda ko ruwan kasa, zubar jini ba zato ba tsammani ko zub da jini mai tsanani ko ba za ka iya sarrafawa ba, amai da jini ko yin amai yayi kama da filayen kofi, tari daga jinni ko ƙulli jini, jiri, rauni, rauni, rikicewa, canje-canje a cikin maganarku, ciwon kai wanda yake ɗaukar lokaci mai tsawo, ko rauni ko alamun launin ja ko purple

Ragewa a cikin ƙididdigar ƙwayoyin jini. Rage ƙididdigar jini (fararen ƙwayoyin jini, platelets, da jajayen ƙwayoyin jini) suna gama gari da Acalabrutinib, amma kuma na iya zama mai tsanani. Ya kamata likitan lafiyar ku yayi gwajin jini don bincika ƙididdigar jinin ku a kai a kai yayin magani tare da Acalabrutinib.

Na biyu na cutar kansa. Sabbin cututtukan daji sun faru a cikin mutane yayin jiyya tare da Acalabrutinib, gami da cututtukan daji na fata ko wasu gabobin. Mai ba da lafiyarku zai bincika ku don cutar kansa ta fata yayin jiyya tare da Acalabrutinib. Yi amfani da kariyar rana lokacin da kake waje a cikin hasken rana.

Matsalar motsawar zuciya (atrial fibrillation da atrial flutter) sun faru a cikin mutanen da aka yiwa magani tare da Acalabrutinib. Faɗa wa mai kula da lafiyar ku idan kuna da ɗayan alamomi ko alamomi masu zuwa: saurin bugun zuciya ko rashin tsari, kumburi, jin suma, rashin jin daɗin kirji, ko numfashi.

Illolin dake tattare da cutar Acalabrutinib sun hada da ciwon kai, gudawa, jijiyoyi da ciwon haɗin gwiwa, kamuwa da cutar numfashi ta sama, da kuma rauni.

Waɗannan ba duk sakamakon tasirin Acalabrutinib bane. Kira likitan ku don shawarar likita game da illa. Kuna iya bayar da rahoton sakamako masu illa ga FDA a 1-800-FDA-1088.

 

Acalabrutinib

 

 

Acalabrutinib VS Ibrutinib

BTK yana taka muhimmiyar rawa a cikin hanyar siginar mai karɓar ƙwayoyin B; acalabrutinib yana ɗaure ba zai yiwu ba ga BTK kuma yana hana aikin sa. An tsara magungunan azaman mai hana zaɓin BTK mai mahimmanci, a cikin yunƙurin rage wasu cututtukan da ke iyakance magungunan da ake gani tare ibrutinib. A cewar Dokta Brown, "Acalabrutinib shine mai hana BTK zabi ga mutanen da ke fama da cututtukan zuciya, musamman matsalolin zuciya."

Bayanai masu inganci sun yi kama da juna tsakanin acalabrutinib da ibrutinib, kodayake bin tsari ya fi tsayi tare da ibrutinib, Dr. Brown ya ci gaba. Sabili da haka, maɓallin banbanci tsakanin magungunan ya ta'allaka ne ga bayanan tasirin su. Ibrutinib yana da ƙarancin haƙuri da haƙuri a cikin tsofaffin majiyyata kuma yana haɗuwa da ƙimar ƙaruwar fibrillation da hauhawar jini. "Acalabrutinib ya fi jurewa fiye da ibrutinib], don haka na yi amfani da shi fifiko, musamman a cikin tsofaffin majiyyata," in ji ta.

Amincewar miyagun ƙwayoyi a cikin CLL, wanda aka bayar a watan Nuwamba na 2019, ya dogara ne da bayanan aminci da inganci daga nazarin wucin gadi na gwajin ELEVATE-TN na marasa lafiya tare da CLL da ba a kula da shi ba a baya da kuma gwajin ASCEND na marasa lafiya tare da sake dawowa ko ƙin yarda da CLL. A cikin duka gwaje-gwajen, acalabrutinib ya nuna rashin ci gaba ba tare da ci gaba ba idan aka kwatanta da daidaitaccen magani, da ingantaccen bayanin martaba. A cikin gwajin ELEVATE-TN, musamman, acalabrutinib haɗe tare da obinutuzumab kuma kamar yadda monotherapy ya rage haɗarin ci gaban cuta ko mutuwa ta 90% da 80%, bi da bi.

"Haƙuri ya kasance batun a cikin yanayin kulawa na yanzu na CLL, wanda na iya buƙatar ci gaba da ci gaba har tsawon shekaru," in ji Jeff Sharman, MD, Daraktan Bincike a Willamette Valley Cancer Cibiyar, Daraktan Kiwon Lafiyar Bincike na Hematology na Cibiyar Kula da Lafiyar Kanjamau ta Amurka, kuma jagorar marubucin gwajin ELEVATE-TN, a cikin sanarwar da aka fitar. "A cikin gwajin ELEVATE-TN da ASCEND da ke kwatanta [acalabrutinib] da tsarin maganin da aka saba amfani da shi, [acalabrutinib] ya nuna ci gaba mai mahimmancin asibiti a ci gaba da rashin ci gaba ga marasa lafiya a fadin saituna da yawa, yayin da yake ci gaba da kasancewa mai jituwa da bayanin martaba."

 

Bincike: Acalabrutinib Akan Kulawa Na kullum lymphocytic cutar sankarar bargo (CLL)  

(1) Na kullum lymphocytic cutar sankarar bargo (CLL)

Kwaro cutar sankarar lymphocytic na yau da kullum (CLL), cutar sankarar bargo mafi girma, ƙwararrakin neoplasm ne wanda aka haɗa shi da ƙananan ƙwayoyin B masu girma waɗanda suke tare CD5 da CD23. Yanayin magani na CLL ya canza sosai a cikin 'yan shekarun nan. Magungunan da ake nufi da sunadarai a cikin hanyar B cell antigen receptor (BCR), kamar ibrutinib, sun nuna ci gaba a cikin ci gaba kyauta da rayuwa gabaɗaya, gami da marasa lafiya da cutar mai haɗari. Kodayake waɗannan kwayoyi sun canza yanayin maganin marasa lafiya tare da CLL, bayyanar magani da ƙarfi tare da ibrutinib na iya iyakance saboda bayanin tasirin sakamako da cututtukan da ke tattare da magani. Acalabrutinib, ƙarni na biyu kuma mai zaɓaɓɓen mai hana Bruton's tyrosine kinase (BTK) mai hanawa, an haɓaka don haɓaka ƙwarewa yayin rage abubuwan ibrutinib da ke tattare da munanan abubuwan da aka ɗauka don zama na biyu ga sakamakon ibrutinib. Wannan bita zai taƙaita ci gaba, kimantawar asibiti, da mahimman gwaji na asibiti waɗanda suka nuna ingancin acalabrutinib da martabar guba a cikin CLL.

 

(2) Nazarin farko na Acalabrutinib a cikin CLL

Yawancin bincike na yau da kullun sun nuna ingancin acalabrutinib akan hana BTK. Lokacin da aka gwada shi akan jinin ɗan adam duka, acalabrutinib yana da hana BTK mai ƙarfi idan aka kwatanta da ibrutinib. An gano Ibrutinib don haifar da ƙara apoptosis na ƙwayoyin CLL idan aka kwatanta da acalabrutinib, wanda za a iya bayanin ta sakamakon abubuwan da aka sa gaba na ibrutinib. Acalabrutinib ba shi da tasiri sosai kan ƙwayoyin T mai ƙoshin lafiya wataƙila saboda zaɓin sa idan aka kwatanta da ibrutinib.

An kimanta tasirin anti-tumor na acalabrutinib a cikin sifofin CLL guda biyu masu murfin ciki: samfurin canja wurin mai karɓa na TCL1 da samfurin CLL na ɗan adam. An nuna Acalabrutinib don hana siginar BCR da magani tare da acalabrutinib yana da alaƙa da haɓakar haɓaka mai girma idan aka kwatanta da berayen da ba a kula da su ba (matsakaicin kwanaki 81 da kwana 59, p = 0.02). Hakanan Acalabrutinib ya haifar da raguwa mai yawa a cikin ƙwayoyin halitta masu haɓaka da nauyin nauyin ƙari a cikin ƙwayar ciki.

Hakanan an kimanta hulɗar Acalabrutinib tare da anti-CD20 monoclonal antibodies. Ibrutinib na iya tsoma baki da yawa daga cikin hanyoyin aiwatar da kwayoyin anti-CD20 musamman hana hana yaduwar kwayar cutar ta cytotoxicity da phagocytosis wanda zai iya rage tasirin kwayar cutar ta su. Golay et al sun kimanta tasirin acalabrutinib akan cytotoxicity na salula mai dogara da antibody kuma ya gano cewa ba ta tsoma baki tare da waɗannan matakan ba, mai yiwuwa saboda ƙananan tasirin tasirin acalabrutinib.Koda yake haɗuwa da acalabrutinib tare da anti-CD20 monoclonal antibody ba a yi nazari ba a cikin samfurin in vivo, da dama lokaci na 2 da na zamani Karatun 3 yana gudana ko kuma an kammala shi wanda ya nuna ingancin acalabrutinib a hade tare da anti-CD20 monoclonal antibody.

Sauran haɗin haɗin acalabrutinib an yi nazarin su a cikin in vitro da cikin sifofin rayuwa. An haɗu da Acalabrutinib tare da mai hana mai PI3Kdelta (ACP-319) a cikin ƙirar CLL na murine kuma ya nuna raguwa mafi girma a cikin haɓakar tumo, siginar NF-KB da bayyana BCL-xL da MCL-1 idan aka kwatanta da maganin jinƙai. ba a shiga cikin gwaji na asibiti ba tare da acalabrutinib da venetoclax.Wannan haɗin an nuna shi don ƙara haɓaka apoptosis idan aka kwatanta da ko dai magungunan ƙwayoyi kaɗai, yana ba da shawarar alaƙar haɗin gwiwa irin wanda aka gani tare da ibrutinib da venetoclax. Wani gwaji na gaba a cikin vivo ya nuna rayuwa mai tsawo a cikin berayen da aka kula da su tare da acalabrutinib da venetoclax idan aka kwatanta da ko dai magungunan kwayoyi kaɗai.

 

(3) karshe

A taƙaice, binciken da aka bayyana ya nuna cewa acalabrutinib yana da fa'ida sosai wajen kula da CLL, duka mahimmancin jiyya da sake komawa baya. Babu tabbaci ko ingancin ya daidaita ko ya fi na ibrutinib kuma karatun na gudana a yunƙurin ƙara kwatanta waɗannan wakilan. Kodayake abubuwan da ke tattare da BTK masu haɗari irin su zub da jini ko al'amuran fibrillation ba su da yawa, acalabrutinib yana da bayanan AE na musamman, musamman ciwon kai, wanda ke buƙatar kulawa da ƙwarewa cikin gudanarwa. Bayanai daga karatun da ke gudana na kimanta haɗuwa tare da acalabrutinib zai taimaka don ƙara bayyana rawar da take takawa a cikin kula da CLL. A ƙarshe, tare da amincewar FDA, ƙwarewar ainihin duniya tare da acalabrutinib zai taimaka don ƙarin ƙayyade bayanin cutar mai guba.

AASraw ƙwararren masani ne na Acalabrutinib.

Da fatan za a danna nan don bayanin zance: Saduwa da mu

 

reference

[1] Hukumar Abinci da Magunguna ta Amurka. Project Orbis: FDA ta amince da acalabrutinib don CLL da SLL. Akwai a https://www.fda.gov/drugs/resources-information-approved-drugs/project-orbis-fda-approves-acalabrutinib-cll-and-sll. An shiga Afrilu 29, 2020.

[2] Sharman JP, Banerji V, Fogliatto LM, et al. ELEVATE-TN: Nazarin 3 na zamani na acalabrutinib haɗe tare da obinutuzumab ko shi kaɗai vs obinutuzumab tare da chlorambucil a cikin marasa lafiya tare da maganin cutar sankarar bargo ta lymphocytic. Jini 2019; 134 (samar da 1): 31.

[3] Sanarwar Latsa AstraZeneca. Calquence da aka amince da ita a Amurka don manya marasa lafiya da ke fama da cutar sankarar bargo ta lymphocytic. Akwai a https://www.astrazeneca.com/media-centre/press-releases/2019/calquence-approved-in-the-us-for-adult-patients-with-chronic-lymphocytic-leukaemia-21112019.html. An shiga Afrilu 29, 2020.

[4] Goede V, Fischer K, Busch R, et al. Obinutuzumab da chlorambucil a cikin marasa lafiya tare da CLL da yanayin rayuwa. N Engl J Med. 2014; 370 (12): 1101-1110. Doi: 10.1056 / NEJMoa1313984.

[5] Parikh SA, Muchtar E, Laplant B, et al. Nazarin 2 na bazuwar gwadawa tare da acalabrutinib tare da ko ba tare da obinutuzumab ba a cikin kula da marasa lafiya masu saurin haɗari tare da Lymphocytic Leukemia na yau da kullun (CLL) ko Lyananan Lymphocytic Lymphoma (SLL). Jini. 2019; 134 (plementarin_1): 4306. Doi: 10.1182 / jini-2019-123824.

[6] Covey T, Gulranjani M, Cheung J, et al. Nazarin Pharmacodynamic na acalabrutinib a cikin sake dawowa / ƙin yarda da marasa lafiya marasa lafiya tare da Cutar Lymphocytic Leukemia (CLL) a cikin Nazarin 1/2 ACE-CL-001. Jini. 2017; 130 (plementarin1): 1741. Doi: 10.1182 / jini.V130.Suppl_1.1741.1741.

[7] Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib da ofatumumab a cikin cutar sankarar bargo ta lymphoid ta yau da kullun. N Engl J Med. 2014; 371 (3): 213–223. Doi: 10.1056 / NEJMoa1400376.

[8] Woyach JA, Bojnik E, Ruppert AS, et al. Aikin Bruton tyrosine kinase (BTK) yana da mahimmanci ga ci gaba da faɗaɗa cutar sankarar bargo ta lymphocytic mai ɗorewa (CLL). Jini. 2014; 123 (8): 1207-1213. Doi: 10.1182 / jini-2013-07-515361.

[9] Chiorazzi N, Rai KR, Ferrarini M. Tsarin cutar sankarar bargo na lymphocytic. N Engl J Med. 2005; 352 (8): 804-815. Doi: 10.1056 / NEJMra041720.

[10] Barr PM, Robak T, Owen C, et al. Effarfafawa mai dorewa da cikakken bin tsarin kulawa na ibrutinib na farko a cikin tsofaffin marasa lafiya tare da cutar sankarar jini na lymphocytic na yau da kullun: sakamako mai tsawo na 3 daga RESONATE-2. Haematologica. 2018; 103 (9): 1502-1510. Doi: 10.3324 / haematol.2018.192328.

[11] Herman SEM, Montraveta A, Niemann CU, et al. Bruton Tyrosine Kinase (BTK) mai hana ACP-196 ya nuna aikin asibiti a cikin nau'ikan linzamin kwamfuta guda biyu na cutar sankarar bargo ta lymphocytic. Jini. 2015; 126 (23): 2920. Doi: 10.1182 / jini.V126.23.2920.2920.

 

 

1 Likes
19 Views

Za ka iya kuma son

Comments an rufe.